 |
VasoMedical to Showcase EECP® Therapy at 2013 European Society of Cardiology Meeting in Amsterdam |
Company Continues to Raise Awareness in the U.S. and Abroad About the Positive Impact Alternative Therapy Can Have for Heart Patients
August 19, 2013 - WESTBURY, N.Y. - VasoMedical, Inc. (“VasoMedical”) (OTCBB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology including EECP® Therapy systems, the gold standard of ECP therapy, announced today that that the Company will attend and exhibit at the 2013 European Society of Cardiology (ESC) Congress taking place from August 31 to September 3, 2013 in Amsterdam, The Netherlands.
The ESC is the largest cardiology show in the world, with 25,000 to 30,000 attendees from all over the globe. Attendees include fellows and members of the ESC as well as members of the 55 European national societies, the American College of Cardiology (ACC) in the United States and members of other international cardiology societies and related healthcare professionals.
VasoMedical will be located in Booth #A420, at the RAI Amsterdam Exhibition and Conference Centre. The Company will present its core technology, EECP® Therapy, as well as its BIOX ECG Holter, ambulatory blood pressure monitors and patient management products.
The Company is pleased to also announce that two abstracts on VasoMedical's EECP® Therapy were accepted to be presented at the Congress. On Sunday, August 31 at 11:00AM local time, Dr. Eline Wu, from the Karolinska Institute in Stockholm, Sweden will make a presentation titled “Enhanced External Counterpulsation for Refractory Angina” in the session discussing chronic care for patients with no cure. This presentation will take place in the Chisinau – Central Village room.
“Dr. Wu has been involved in EECP® Therapy research at this prestigious institution for many years,” stated Larry Liebman, Vice President of Sales and Marketing at VasoMedical. “Her knowledge and experience on the subject will make a great contribution to our effort to increase awareness about EECP® Therapy among this group of health professionals.”
On Monday, September 2 at 2:00PM local time, Dr. Vyacheslav Ryabov from Tomsk, Russia will present his poster (P4019) titled “Effects of Enhanced External Counterpulsation on Endothelial Function and Antithrombogenic Activity of Vascular Endothelium in Patients with Angina” during Poster Session 5.
“Dr. Ryabov was one of the first physicians in the Russian Federation to introduce EECP® Therapy as an effective adjunctive treatment and has studied and reported his results at major cardiology conferences and symposia in Russia for the past several years,” said Mr. Liebman. “Having these two abstracts on EECP® Therapy selected for presentation at the ESC, from the over 9,000 abstracts submitted, is an honor for these physicians and their institutions and also highlights that there is a significant interest in learning more about EECP® Therapy and its positive effects on treating cardiovascular disease.”
About VasoMedical
VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company's main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, VasoMedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; VasoMedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at www.vasomedical.com
About BIOX Instruments
BIOX Instruments Co., Ltd., a wholly owned subsidiary of VasoMedical, is based in Wuxi, Jiangsu Province, China. With long established expertise in miniaturization and low power consumption medical devices, it is a leading company in ambulatory monitoring systems consisting of ECG Holter recorders, ambulatory blood pressure monitoring (ABPM) systems as well as related analysis and reporting software. BIOX is in full compliance of revered quality and manufacturing standards such as ISO 13485, ISO 9001, US FDA cGMP as well as the Medical Device Directive of the European Union. BIOX products are FDA Cleared, CE Marked and Health Canada Listed. Furthermore, BIOX continues to provide OEM and OED services to many businesses that require effective solutions to product design and performance. Additional information is available on the Company's website at http://www.biox.com.cn.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com
Media Contacts:
Lewis Goldberg / Samantha Wolf
KCSA Strategic Communications
212-896-1216 / 212-896-1220
lgoldberg@kcsa.com / swolf@kcsa.com